Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzarone SCHEMBL22658418 | 0.85 | SLC22A12 (0.67) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287600 | 0.82 | SLC22A12 (0.88) | SLC22A12CYP2C9EYA3CYP2C19L3MBTL1 | |
| SCHEMBL1287462 | 0.82 | CYP2C9 (0.83) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287565 | 0.82 | SLC22A12 (0.88) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287515 | 0.79 | SLC22A12 (0.86) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287500 | 0.79 | SLC22A12 (0.86) | SLC22A12CYP2C9EYA3CYP2C19 | |
| SCHEMBL1287903 | 0.78 | SLC22A12 (0.72) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287502 | 0.76 | SLC22A12 (1.00) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL1287454 | 0.76 | SLC22A12 (1.00) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 | |
| SCHEMBL22658407 | 0.75 | CYP2C19 (0.55) | SLC22A12CYP2C9EYA3CYP2C19NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419854-B2 | Methods for treating or preventing gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250066316-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| US-20250059150-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12145917-B2 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | ARTHROSI THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-116648445-A | Methods for treating or preventing chronic kidney disease | 安索治疗公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-113226302-B | Crystalline forms of a compound for the treatment or prophylaxis of gout or hyperuricemia | 广州瑞安博医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023098872-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4164624-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | Arthrosi Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220242841-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3968989-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | Arthrosi Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020232156-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419854-B2 | Methods for treating or preventing gout or hyperuricemia | CYP27B1, XDH, CYP27A1 | SLC22A12 830/4885CYP2C9 675/4885EYA3 4761/4885 |
| US-20220024889-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | SLC22A12 854/4885CYP2C9 482/4885EYA3 4702/4885 |
| US-20220023251-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27B1, XDH, CYP27A1 | SLC22A12 830/4885CYP2C9 675/4885EYA3 4761/4885 |
| US-20220242841-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | CYP27A1, CYP27B1, XDH | SLC22A12 564/4885CYP2C9 759/4885EYA3 4415/4885 |
| US-20250066316-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | SLC22A12 854/4885CYP2C9 482/4885EYA3 4702/4885 |
| US-12145917-B2 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | CYP27A1, CYP24A1, CYP27B1 | SLC22A12 854/4885CYP2C9 482/4885EYA3 4702/4885 |
| US-20250059150-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | CYP27A1, CYP24A1, CYP27B1 | SLC22A12 854/4885CYP2C9 482/4885EYA3 4702/4885 |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | SLC22A12 620/4885CYP2C9 1394/4885EYA3 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.